Operative Techniques in Orthopaedics
Volume 16, Issue 4 , Pages 271-278, October 2006

BST-CarGel: In Situ ChondroInduction for Cartilage Repair

  • Matthew S. Shive, PhD

      Affiliations

    • BioSyntech Canada Inc., Laval, Quebec, Canada.
    • Corresponding Author InformationAddress reprint requests to Matthew S. Shive, PhD, BioSyntech Canada Inc, 475 Armand-Frappier Boulevard, Laval, Quebec H7V 4B3, Canada.
  • ,
  • Caroline D. Hoemann, PhD

      Affiliations

    • Chemical Engineering and Institute of Biomedical Engineering, École Polytechnique, Montreal, Quebec, Canada.
  • ,
  • Alberto Restrepo, MD

      Affiliations

    • BioSyntech Canada Inc., Laval, Quebec, Canada.
  • ,
  • Mark B. Hurtig, DVM

      Affiliations

    • Comparative Orthopaedic Research Laboratory, Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
  • ,
  • Nicolas Duval, MD

      Affiliations

    • Duval Orthopedic Clinic, Laval, Quebec, Canada.
  • ,
  • Pierre Ranger, MD

      Affiliations

    • Department of Surgery, University of Montreal, Montreal, Quebec, Canada.
  • ,
  • William Stanish, MD

      Affiliations

    • Division of Orthopaedic Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.
  • ,
  • Michael D. Buschmann, PhD

      Affiliations

    • Chemical Engineering and Institute of Biomedical Engineering, École Polytechnique, Montreal, Quebec, Canada.

The repair of articular cartilage has posed a longstanding orthopedic challenge. The concept of marrow stimulation is basically the intentional injury of a subchondral bone below a cartilage lesion to elicit a wound repair response. However, the desire to fill the lesion with a blood clot is at odds with platelet-driven clot retraction, which results in clot shrinkage and detachment. Therefore, BST-CarGel was developed to produce a physically stabilized blood clot that is more voluminous and adherent within a debrided cartilage lesion having access to bone marrow, thus improving existing bone marrow-stimulation procedures. BST-CarGel is a soluble polymer scaffold containing the polysaccharide chitosan, which is dispersed throughout uncoagulated whole blood, and then delivered to a surgically prepared lesion. BST-CarGel allows normal clot formation, reinforces the clot, impedes retraction, increases adhesivity, and ensures prolonged residency of both the clot and critical tissue repair factors from blood. In animals, BST-CarGel was shown to increase the volume and hyaline character of repair tissue, with increased GAG and collagen content, compared with microfracture controls. A patient cohort received BST-CarGel treatment, which encompassed the spectrum of traumatic to degenerative lesions, along with other joint pathologies. Anecdotal evidence demonstrated the potential of BST-CarGel for treating focal cartilage lesions of variable etiology through both mini-open and arthroscopic approaches. Because it requires only a single minimally invasive intervention, BST-CarGel and its unique characteristics are novel in orthopedics. In addition, its use with marrow stimulation provides familiarity with well-recognized surgical techniques, bringing a simple-yet-versatile treatment modality that applies scaffold-guided regenerative medicine to a potentially wide-ranging group of indications.

Keywords: cartilage repair, implant, arthroscopy, scaffold, chitosan, osteoarthritis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors acknowledge funding sources for animal studies, which include BioSyntech Canada Inc, Canadian Institutes of Health Research (CIHR), Canadian Arthritis Networks of Centres of Excellence (CAN), and Canada Research Chairs (CRC).

PII: S1048-6666(06)00072-3

doi:10.1053/j.oto.2006.08.001

Operative Techniques in Orthopaedics
Volume 16, Issue 4 , Pages 271-278, October 2006